Treatment-Resistant Depression: When Standard Antidepressants Aren't Enough

You did everything your doctor said. You took the first medication for 8 weeks. It didn't help. So they switched you to another one. That one gave you side effects that felt worse than the depression. So you tried a third. Maybe a fourth. Each time, you waited the 4-6 weeks, hoping this one would be different. And each time, you ended up back where you started: exhausted, discouraged, and wondering if anything will actually work.

That experience has a clinical name: treatment-resistant depression. It affects an estimated 30-40% of people with major depressive disorder, according to research published in The American Journal of Psychiatry. If two or more adequate antidepressant trials haven't produced meaningful improvement, you're in this category. It doesn't mean depression is untreatable. It means the most common treatments haven't worked for you yet, and different approaches exist.

Key Facts

• Definition: Depression that hasn't responded to at least two adequate trials of antidepressant medication at proper doses and durations
• Prevalence: Approximately 30-40% of MDD patients, or roughly 6-8 million U.S. adults
• Commonly confused with: Undertreated depression (inadequate dose/duration), misdiagnosed bipolar depression, medication non-adherence, co-occurring conditions masking response
• When to see a provider: If you've been on two or more antidepressants at adequate doses for adequate durations without significant improvement

Symptoms of Treatment-Resistant Depression

The symptoms of TRD are the same as major depressive disorder, the difference is in the response to treatment, not the symptom profile. That said, TRD patients often experience certain patterns:

• Persistent depressed mood despite medication adherence
• Ongoing functional impairment at work, in relationships, and in self-care
• Partial response: some symptoms improve but significant residual depression remains
• Fatigue and cognitive difficulties that don't resolve with antidepressant treatment
• Ongoing sleep disturbance despite medication
• Anhedonia (inability to feel pleasure) that persists through multiple medication trials
• Increasing hopelessness, often compounded by the repeated experience of treatments not working

The psychological toll of TRD extends beyond the depression itself. Each failed medication trial erodes confidence in treatment. Many people with TRD develop secondary hopelessness: they're not just depressed, they've lost faith that anything can help. That hopelessness is a symptom of the treatment experience, not a reflection of reality.

These symptoms may indicate treatment-resistant depression, but only a qualified provider can determine whether your depression meets TRD criteria. True treatment resistance requires verification that prior medication trials were adequate in dose and duration.

What Causes Treatment-Resistant Depression

TRD isn't a separate disease from MDD. It's a descriptor for how MDD responds, or fails to respond, to treatment. Several factors contribute:

Biological factors:

• Pharmacogenomics. Genetic variations in drug-metabolizing enzymes (CYP2D6, CYP2C19) affect how you process antidepressants. Ultra-rapid metabolizers may break down medications before they can work. Poor metabolizers may accumulate side effects at standard doses. Pharmacogenomic testing can identify these variations.
• Neuroinflammation. Elevated inflammatory markers (CRP, IL-6, TNF-alpha) are more common in TRD patients and may represent a depression subtype that responds differently to treatment.
• Glutamate system dysfunction. Standard antidepressants target serotonin and norepinephrine. Emerging research suggests that glutamate, the brain's primary excitatory neurotransmitter, plays a central role in TRD, which is why ketamine (a glutamate modulator) shows efficacy in this population.
• HPA axis dysregulation. Chronic stress alters cortisol regulation, which can perpetuate depression and reduce antidepressant efficacy.

Treatment-related factors:

• Inadequate dose or duration of prior trials (the most common "false TRD")
• Side effects causing patients to stop medication before it reaches therapeutic effect
• Drug interactions reducing efficacy
• Poor medication adherence (missed doses compound over time)

Co-occurring factors:

• Undiagnosed bipolar disorder (antidepressants alone often fail in bipolar depression and can worsen it)
• Co-occurring anxiety, substance use, PTSD, or personality disorders
• Chronic pain or chronic medical illness
• Persistent psychosocial stressors (housing instability, financial crisis, abusive relationships)
• Sleep disorders, particularly untreated obstructive sleep apnea

Before accepting a TRD label, your provider should verify that prior trials were truly adequate and that contributing factors have been addressed.

How Treatment-Resistant Depression Is Diagnosed

There's no biomarker for TRD. Diagnosis is based on treatment history, not a blood test.

Standard criteria:

• Confirmed diagnosis of major depressive disorder
• Failure to achieve remission (or adequate response) with at least two antidepressant trials
• Each trial must have been at an adequate dose for an adequate duration (typically at least 4-6 weeks at therapeutic dose)
• Medication adherence must be confirmed (not assumed)

The evaluation process:

• Complete medication history: every antidepressant tried, at what dose, for how long, and what happened
• Assessment of response versus side-effect-driven discontinuation (these are different things)
• Screening for misdiagnosis: bipolar disorder (especially Bipolar II), ADHD, personality disorders, thyroid dysfunction
• Lab work: thyroid panel, vitamin D, B12, CBC, metabolic panel
• Pharmacogenomic testing may be considered to guide future medication selection
• Psychosocial assessment: are there ongoing stressors that no medication can fix?
• Assessment for substance use
• Suicide risk evaluation (TRD patients have elevated suicide risk relative to treatment-responsive depression)

Treatment Options for Treatment-Resistant Depression

If standard antidepressants haven't worked, the conversation shifts to a different set of options. These aren't experimental or fringe. They're evidence-based treatments specifically studied in TRD populations.

Medication optimization strategies:

• Augmentation. Adding a second medication to an existing antidepressant. Common augmentation agents include atypical antipsychotics, lithium, and thyroid hormone. Augmentation is often the first step.
• Switching medication class. Moving from an SSRI to an SNRI, or to an atypical antidepressant like bupropion or mirtazapine.
• Combination therapy. Using two antidepressants from different classes simultaneously.
• Pharmacogenomic-guided prescribing. Using genetic test results to choose medications your body is more likely to metabolize effectively.

Ketamine therapy:

Ketamine works through a fundamentally different mechanism than traditional antidepressants. It modulates the glutamate system and promotes rapid synaptic plasticity through BDNF (brain-derived neurotrophic factor) release.

• Racemic ketamine (IV or IM) is used off-label for treatment-resistant depression. Clinical studies have shown that some patients may experience improvement in depressive symptoms within hours to days, though individual results vary. An induction series typically involves 6 sessions over 2-3 weeks, followed by maintenance as needed.
• Ketamine is a Schedule III controlled substance administered only under medical supervision. It is not a first-line treatment and is not effective for everyone. Side effects include dissociation, nausea, elevated blood pressure, and dizziness during the infusion.

At Ascend, ketamine therapy is administered by Anna Stouffer, PMHNP-BC, in a monitored clinical setting.

Neuromodulation therapies:

• Transcranial Magnetic Stimulation (TMS). FDA-cleared for TRD. Uses magnetic pulses to stimulate the prefrontal cortex. Typical course is 30-36 sessions over 6-9 weeks. Generally well-tolerated with minimal systemic side effects.
• Electroconvulsive Therapy (ECT). The most effective treatment for severe, refractory TRD, with response rates of 50-70%. Administered under general anesthesia. Primarily reserved for severe cases, particularly with psychotic features or acute suicidality.
• Vagus Nerve Stimulation (VNS). FDA-approved for TRD but less commonly used due to surgical implantation requirement and variable response rates.

Psychotherapy (alongside other interventions):

Therapy alone rarely resolves TRD, but it plays an important supporting role. CBT, behavioral activation, and acceptance-based approaches help manage residual symptoms, address cognitive patterns, and improve functioning even when depressive symptoms persist.

When to See a Provider

If you've been on two or more antidepressants without improvement, you've earned a more thorough evaluation. This isn't about "trying harder" or "being patient." You've already been patient.

Seek specialized evaluation if:

• Two or more antidepressants at adequate doses haven't worked
• You've experienced partial response but still feel significantly impaired
• Side effects keep forcing you off medications before they can work
• You've been treated for depression but you're not sure anyone has thoroughly evaluated whether it's actually unipolar depression
• You're interested in exploring ketamine therapy, TMS, or other non-traditional options

How Ascend Treats Treatment-Resistant Depression

At Ascend Mind and Body, TRD is where our psychiatry and ketamine therapy practices intersect. Anna Stouffer, PMHNP-BC evaluates patients with treatment-resistant depression and builds individualized plans that may include medication optimization, ketamine therapy, and referrals for TMS or other neuromodulation.

Your first visit involves a comprehensive review of your treatment history. We want to see every medication you've tried, at what dose, for how long, and what the response was. We also screen for misdiagnosis and co-occurring conditions that may be contributing to treatment resistance.

If ketamine is appropriate, we discuss the process in detail: what to expect during sessions, the typical treatment course, realistic outcomes, side effects, and costs. Racemic ketamine is typically a cash-pay service.

our providers are in-network with Aetna, Cigna, UnitedHealthcare, Medicare, Medicaid, TRICARE, AARP, and ChampVA for psychiatric evaluations and medication management. Ketamine therapy pricing is discussed during your consultation. Visit our new patients page to schedule.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for diagnosis and treatment.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for diagnosis and treatment.